Recurrent Mantle Cell Lymphoma Terminated Phase 1 Trials for Ibrutinib (DB09053)

Also known as: Mantle Cell Lymphoma Recurrent

IndicationStatusPhase
DBCOND0028615 (Recurrent Mantle Cell Lymphoma)Terminated1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02109224Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV InfectionTreatment